{"id":745115,"date":"2015-09-26T06:00:00","date_gmt":"2015-09-26T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\/"},"modified":"2025-11-07T01:24:56","modified_gmt":"2025-11-07T06:24:56","slug":"new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\/","title":{"rendered":"New Findings Show Anti-Tumor Activity of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma"},"content":{"rendered":"<p class=\"bwalignc\">       KEYTRUDA Monotherapy Achieved Overall Response Rate of 22.2 Percent        in Previously-Treated Patients     <\/p>\n<p class=\"bwalignc\">       Results from KEYNOTE-028 Presented at 2015 European Cancer Congress     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the first-time presentation of findings investigating<br \/>\n      the use of KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s anti-PD-1<br \/>\n      therapy, as a monotherapy in patients with advanced unresectable<br \/>\n      nasopharyngeal carcinoma (NPC) \u2013 a type of head and neck cancer \u2013 whose<br \/>\n      tumors express PD-L1 (\u22651% of cells in tumor nests or PD-L1+ bands in<br \/>\n      stroma). Data were from a Phase 1b study (KEYNOTE-028) and showed an<br \/>\n      overall response rate (ORR) (confirmed and unconfirmed) of 22.2 percent<br \/>\n      (95% CI, 8.6-42.3) in evaluable patients (n=27) who were treated with<br \/>\n      KEYTRUDA. Results were presented in an oral session by Dr. Chiun Hsu,<br \/>\n      National Taiwan University Hospital, at the European Cancer Congress<br \/>\n      (ECC) in Vienna (Abstract #2801).\n    <\/p>\n<p>\n      \u201cAdvanced nasopharyngeal carcinoma is a severe form of head and neck<br \/>\n      cancer often associated with a poor prognosis,\u201d said Dr. Hsu. \u201cThese<br \/>\n      data presented at ECC represent the potential for new approaches to<br \/>\n      treat this type of cancer, for which there are currently limited<br \/>\n      treatment options, and further support the need for additional research<br \/>\n      into how KEYTRUDA may work for certain types of head and neck cancer.\u201d\n    <\/p>\n<p>\n      Merck has initiated a comprehensive clinical development program<br \/>\n      evaluating KEYTRUDA in head and neck cancer across multiple lines of<br \/>\n      therapy as monotherapy and in combination with chemotherapy as well as<br \/>\n      other agents. In KEYNOTE-028, KEYTRUDA is being evaluated in patients<br \/>\n      with advanced unresectable NPC that is not responding to current therapy<br \/>\n      or for which current therapy is not appropriate. This is the second<br \/>\n      study to show early activity of KEYTRUDA in patients with head and neck<br \/>\n      cancer and the first study of an anti-PD-1 therapy to demonstrate<br \/>\n      clinical activity in patients with recurrent or metastatic NPC. For more<br \/>\n      information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.keynoteclinicaltrials.com&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=www.keynoteclinicaltrials.com&amp;index=1&amp;md5=b449a1b40d2e5c3571dfd3bbc6ec9430\" rel=\"nofollow\">www.keynoteclinicaltrials.com<\/a>.\n    <\/p>\n<p>\n      \u201cThe findings emerging from this trial again demonstrate that KEYTRUDA<br \/>\n      is active across a broad range of cancers, including those that are<br \/>\n      difficult to treat with standard treatments,\u201d said Dr. Roger Dansey,<br \/>\n      senior vice president and therapeutic area head, oncology late-stage<br \/>\n      development, Merck Research Laboratories. \u201cBased on these and other<br \/>\n      results to date, we are continuing to advance a comprehensive head and<br \/>\n      neck clinical program for KEYTRUDA, and we remain focused on realizing<br \/>\n      its full potential to address the unmet treatment needs for patients<br \/>\n      with difficult-to-treat cancers such as nasopharyngeal carcinoma.\u201d\n    <\/p>\n<p>\n      <b>Additional Nasopharyngeal Carcinoma Results from KEYNOTE-028<\/b>\n    <\/p>\n<p>\n      KEYNOTE-028 is an ongoing multi-cohort, non-randomized Phase 1b basket<br \/>\n      trial (a trial design that allows for the study of multiple<br \/>\n      sub-populations of different tumor or histological types within one<br \/>\n      study) evaluating the safety, tolerability, and anti-tumor activity of<br \/>\n      KEYTRUDA monotherapy (10 mg\/kg dosed every two weeks) in more than 450<br \/>\n      patients across 20 different types of cancer. The study was designed to<br \/>\n      evaluate patients with advanced solid tumors that express PD-L1 and<br \/>\n      which have not responded to current therapy or for which current therapy<br \/>\n      is not appropriate.\n    <\/p>\n<p>\n      These early findings from 27 heavily pre-treated patients with advanced<br \/>\n      NPC demonstrated an ORR of 22.2 percent (n=6\/27) (per RECIST v1.1),<br \/>\n      including six partial responses (95% CI, 8.6-42.3). Additionally, 55.6<br \/>\n      percent of patients had stable disease (n=15\/27) (95% CI, 35.3-74.5),<br \/>\n      the disease control rate (DCR) was 77.8 percent (n=21\/27) (95% CI,<br \/>\n      57.7-91.4), and tumor shrinkage was achieved in 67 percent of patients.<br \/>\n      The 6-month progression-free survival (PFS) rate was 49.7 percent and<br \/>\n      the 12-month PFS rate was 28.9 percent. The median follow-up duration<br \/>\n      for evaluable patients was 12.9 months (range, 2.2\u221215.0) and the median<br \/>\n      response duration was 10.8 months (range, 4.8- 10.8).\n    <\/p>\n<p>\n      Adverse events were generally consistent with previously reported safety<br \/>\n      data for KEYTRUDA. Grade 3-5 investigator-assessed, treatment-related<br \/>\n      adverse events were hepatitis (n=2), pneumonitis (n=2), anemia (n=1),<br \/>\n      facial pain (n=1), increased blood creatine phosphokinase (n=1),<br \/>\n      proteinuria (n=1), and sepsis (n=1). Immune-mediated adverse events were<br \/>\n      hypothyroidism (n=5), hepatitis (n=4), and pneumonitis (n=3). There was<br \/>\n      one treatment-related death due to bacterial sepsis.\n    <\/p>\n<p>\n      <b>About PD-L1 and PD-L1 Expression<\/b>\n    <\/p>\n<p>\n      PD-L1, also called programmed death-ligand 1, is a protein expressed on<br \/>\n      many types of cells, including some cancer cells. Under normal<br \/>\n      conditions, the interaction of PD-L1 with another protein, called<br \/>\n      programmed death receptor-1 (PD-1), serves as an important immune system<br \/>\n      checkpoint, keeping the immune system in balance and preventing the body<br \/>\n      from attacking its own cells when inflammation or an infection is<br \/>\n      present. When cancerous tumors express PD-L1, however, they are able to<br \/>\n      escape detection and destruction by cytotoxic T-cells \u2013 a type of<br \/>\n      cancer-killing immune cell \u2013 allowing the tumor to survive and grow.<br \/>\n      Tumor PD-L1 expression has been observed at varying levels across many<br \/>\n      tumor types, including breast, lung, bladder cancer, and nasopharyngeal<br \/>\n      carcinoma. High levels of PD-L1 expression, called overexpression, are<br \/>\n      under investigation for potential use as a way to help identify patients<br \/>\n      with an enhanced likelihood to respond to certain immune-based treatment<br \/>\n      approaches.\n    <\/p>\n<p>\n      <b>About Nasopharyngeal Cancer<\/b>\n    <\/p>\n<p>\n      Nasopharyngeal cancer (NPC) is a type of head and neck cancer that<br \/>\n      starts in the epithelial cells that line the surface of the nasopharynx,<br \/>\n      the upper part of the throat behind the nose and near the base of skull.<sup>1<\/sup><br \/>\n      There are three types of NPC, based on how the cancer cells look under<br \/>\n      the microscope: keratinizing squamous cell carcinoma, non-keratinizing<br \/>\n      differentiated carcinoma, and undifferentiated carcinoma.<sup>1<\/sup><br \/>\n      Leading risk factors for NPC include Chinese or Asian ancestry, being<br \/>\n      exposed to the Epstein-Barr virus, and drinking large amounts of alcohol.<sup>2<\/sup><br \/>\n      In most parts of the world (including the United States), there is less<br \/>\n      than one case of NPC for every 100,000 people each year.<sup>3<\/sup> In<br \/>\n      2015, about 3,200 cases of NPC are expected to occur in the United<br \/>\n      States.<sup>3<\/sup>\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that blocks the interaction<br \/>\n      between PD-1 and its ligands, PD-L1 and PD-L2. By binding to the PD-1<br \/>\n      receptor and blocking the interaction with the receptor ligands,<br \/>\n      KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune<br \/>\n      response, including the anti-tumor immune response. KEYTRUDA is<br \/>\n      indicated for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma and disease progression following ipilimumab and, if BRAF V600<br \/>\n      mutation positive, a BRAF inhibitor. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. An improvement in survival or disease-related symptoms has not<br \/>\n      yet been established. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      The KEYTRUDA clinical development program has rapidly expanded to<br \/>\n      encompass more than 30 tumor types in more than 130 clinical trials, of<br \/>\n      which more than 70 trials combine KEYTRUDA with other cancer treatments.<br \/>\n      Registration-enabling trials of KEYTRUDA monotherapy are currently<br \/>\n      enrolling patients in melanoma, NSCLC, head and neck cancer, bladder<br \/>\n      cancer, gastric cancer, colorectal cancer, and Hodgkin Lymphoma, with<br \/>\n      further trials in planning for other cancers.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients, including Grade 2 or<br \/>\n      3 cases in 8 (1.9%) and 1 (0.2%) patients, respectively, receiving<br \/>\n      KEYTRUDA. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%)<br \/>\n      patients, respectively, receiving KEYTRUDA. Monitor patients for signs<br \/>\n      and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients, respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, has occurred<br \/>\n      in patients receiving KEYTRUDA. Monitor patients for hyperglycemia and<br \/>\n      other signs and symptoms of diabetes. Administer insulin for type 1<br \/>\n      diabetes, and withhold KEYTRUDA in cases of severe hyperglycemia until<br \/>\n      metabolic control is achieved.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients, consisting of one case of Grade<br \/>\n      2 autoimmune nephritis (0.2%) and two cases of interstitial nephritis<br \/>\n      with renal failure (0.5%), one Grade 3 and one Grade 4. Monitor patients<br \/>\n      for changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in patients treated with KEYTRUDA: exfoliative dermatitis,<br \/>\n      uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial<br \/>\n      seizures arising in a patient with inflammatory foci in brain<br \/>\n      parenchyma, severe dermatitis including bullous pemphigoid, myasthenic<br \/>\n      syndrome, optic neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Infusion-related reactions, including severe and life-threatening<br \/>\n      reactions, have occurred in patients receiving KEYTRUDA. Monitor<br \/>\n      patients for signs and symptoms of infusion-related reactions including<br \/>\n      rigors, chills, wheezing, pruritus, flushing, rash, hypotension,<br \/>\n      hypoxemia, and fever. For severe or life-threatening reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued for adverse reactions in 9% of 411 patients.<br \/>\n      Adverse reactions, reported in at least two patients, that led to<br \/>\n      discontinuation of KEYTRUDA were: pneumonitis, renal failure, and pain.<br \/>\n      Serious adverse reactions occurred in 36% of patients. The most frequent<br \/>\n      serious adverse reactions, reported in 2% or more of patients, were<br \/>\n      renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in at least 20% of patients)<br \/>\n      were fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash<br \/>\n      (29%), decreased appetite (26%), constipation (21%), arthralgia (20%),<br \/>\n      and diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=4795aeb55f1106cfbffb1cfc948d3622\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=58be7b15f31eae84af61cfc8fefc9e70\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><span class=\"bwuline\"><br \/>\n      <\/span>and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2F1jWVIedEI8Ie3D1Ob9KVJd5AsYeKCYedFEIzDxRSmkjqqb8VUttdVUSzt4QsEKnsohdG_6NmIblfGhbj_lgkoIIhfGgQ_BPpyON4-F3j-ndKKnojvovW_3AT-LsKCO-ZOb8UtORQr8EGTjjVkffGhBrwqrhdLCXCXCOsVHkiP9C9jDYunNnUSaCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96QrzztxwgD7GV&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=1b35b537ed8feb16709f441757388f9d\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2F1jWVIgdEI8Ie3D1Ob9KVJd5AsYeKCYedFEIzDxRSmkjqqb8VUttdVUSzt4QsEKnsohdG_6NmIblfGhbj_lgkoIIhfGgQ_BPpyON4-F3j-ndKKnojvovW_3AT-LsKCO-ZOb8UtORQr8EGTjjVkffGhBrwqrjdLCXCXCM0jKSYxmFnBYl-dyF3P7DDCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96Qrzzu-jj&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=ce0a408c39e1a70a5e31df8a9c960441\" rel=\"nofollow\">Facebook<\/a><span class=\"bwuline\"><br \/>\n      <\/span>and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2FavndzgA76Qm4m71PwV5ATsSCyOeu7nju76QQmhPMWXba9Jd5AsYeKCYYrhKyqeknbKc8CRvzoHm5GDR8BF_GEacmm8DR8qvOVINpoyvkxF_bCTnbI9LIfZvxOr_nKnjpvuV5AseVqWdAklrFFYG7DR8OJMddICTPtPtPo08JlKrp3-nNnUSaCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96QrzzqvgF&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=d94278622656a9d0200c066f4065dce1\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the Company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the Company\u2019s s<br \/>\n      patents and other protections for innovative products; and the exposure<br \/>\n      to litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=56784f1bfff5e877a37689b09fb82fd8\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <span class=\"bwuline\">References<\/span>\n    <\/p>\n<p>\n      1. <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fnasopharyngealcancer%2Fdetailedguide%2Fnasopharyngeal-cancer-what-is-nasopharyngeal-cancer&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fnasopharyngealcancer%2Fdetailedguide%2Fnasopharyngeal-cancer-what-is-nasopharyngeal-cancer&amp;index=8&amp;md5=2dc0c7e955f175ea35780c1311dece51\" rel=\"nofollow\">http:\/\/www.cancer.org\/cancer\/nasopharyngealcancer\/detailedguide\/nasopharyngeal-cancer-what-is-nasopharyngeal-cancer<\/a>\n    <\/p>\n<p>\n      2. <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fhead-and-neck%2Fpatient%2Fnasopharyngeal-treatment-pdq&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fhead-and-neck%2Fpatient%2Fnasopharyngeal-treatment-pdq&amp;index=9&amp;md5=17039b47827c0b3ae0cec80d93e53df2\" rel=\"nofollow\">http:\/\/www.cancer.gov\/types\/head-and-neck\/patient\/nasopharyngeal-treatment-pdq<\/a>\n    <\/p>\n<p>\n      3. <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fnasopharyngealcancer%2Fdetailedguide%2Fnasopharyngeal-cancer-key-statistics&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.cancer.org%2Fcancer%2Fnasopharyngealcancer%2Fdetailedguide%2Fnasopharyngeal-cancer-key-statistics&amp;index=10&amp;md5=8a3b151693eaec5ae850d36bcbfa41aa\" rel=\"nofollow\">http:\/\/www.cancer.org\/cancer\/nasopharyngealcancer\/detailedguide\/nasopharyngeal-cancer-key-statistics<\/a>\n    <\/p>\n<p>\n      Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=11&amp;md5=c1699bd06d324cd8b0e9db35eb469b91\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/a><br \/>\n      and the Medication Guide for KEYTRUDA at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51189077&amp;newsitemid=20150926005018&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=12&amp;md5=4f95b0ec230ac19a5a4d26384ddb0993\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/a>.\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150926005018r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, (267) 305-3558<br \/>An Phan, (908)        255-6325<br \/>or<br \/>Investor:<br \/>Justin Holko, (908) 740-1879<br \/>Teri        Loxam, (908) 740-1986     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy in patients with advanced unresectable nasopharyngeal carcinoma (NPC) \u2013 a type of head and neck cancer \u2013 whose tumors express PD-L1 (\u22651% of cells in tumor nests or PD-L1+ bands in stroma). Data were from a Phase 1b study (KEYNOTE-028) and showed an overall response rate (ORR) (confirmed and unconfirmed) of 22.2 percent (95% CI, 8.6-42.3) in evaluable patients (n=27) who were treated with KEYTRUDA. Results were presented in an oral session by Dr. Chiun Hsu, National Taiwan University Hospital, at the European Cancer Congress (ECC) in Vienna (Abstract #2801). \u201cAdvanced nasopharyngeal carcinoma is a severe form of head and neck cancer often associated with a poor prognosis,\u201d said Dr. Hsu. \u201cThese data presented at ECC represent the potential for new approaches to<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745115","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Findings Show Anti-Tumor Activity of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Findings Show Anti-Tumor Activity of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy in patients with advanced unresectable nasopharyngeal carcinoma (NPC) \u2013 a type of head and neck cancer \u2013 whose tumors express PD-L1 (\u22651% of cells in tumor nests or PD-L1+ bands in stroma). Data were from a Phase 1b study (KEYNOTE-028) and showed an overall response rate (ORR) (confirmed and unconfirmed) of 22.2 percent (95% CI, 8.6-42.3) in evaluable patients (n=27) who were treated with KEYTRUDA. Results were presented in an oral session by Dr. Chiun Hsu, National Taiwan University Hospital, at the European Cancer Congress (ECC) in Vienna (Abstract #2801). \u201cAdvanced nasopharyngeal carcinoma is a severe form of head and neck cancer often associated with a poor prognosis,\u201d said Dr. Hsu. \u201cThese data presented at ECC represent the potential for new approaches to\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\\\/\",\"name\":\"New Findings Show Anti-Tumor Activity of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-09-26T06:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Findings Show Anti-Tumor Activity of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Findings Show Anti-Tumor Activity of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\/","og_locale":"en_US","og_type":"article","og_title":"New Findings Show Anti-Tumor Activity of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as a monotherapy in patients with advanced unresectable nasopharyngeal carcinoma (NPC) \u2013 a type of head and neck cancer \u2013 whose tumors express PD-L1 (\u22651% of cells in tumor nests or PD-L1+ bands in stroma). Data were from a Phase 1b study (KEYNOTE-028) and showed an overall response rate (ORR) (confirmed and unconfirmed) of 22.2 percent (95% CI, 8.6-42.3) in evaluable patients (n=27) who were treated with KEYTRUDA. Results were presented in an oral session by Dr. Chiun Hsu, National Taiwan University Hospital, at the European Cancer Congress (ECC) in Vienna (Abstract #2801). \u201cAdvanced nasopharyngeal carcinoma is a severe form of head and neck cancer often associated with a poor prognosis,\u201d said Dr. Hsu. \u201cThese data presented at ECC represent the potential for new approaches to","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:56+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\/","name":"New Findings Show Anti-Tumor Activity of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-09-26T06:00:00+00:00","dateModified":"2025-11-07T06:24:56+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-findings-show-anti-tumor-activity-of-keytruda-pembrolizumab-in-patients-with-advanced-nasopharyngeal-carcinoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New Findings Show Anti-Tumor Activity of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"255bf221-80c7-4319-8b3a-495ce84c1f36","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-Findings-Show-Anti-Tumor-Activity-of-KEYTRUDA-pembrolizumab-in-Patients-with-Advanced-Nasopharyngeal-Carcinoma-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745115\/revisions"}],"predecessor-version":[{"id":3674596,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745115\/revisions\/3674596"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745115"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}